Member Info for mulledwine

http://www.investegate.co.uk/Article.aspx?id=201112020700152231T

ommenting on the Acquisition, Chris Meredith, Chief Executive Officer of AMS said: "Part of our core growth strategy has been to examine potential acquisition opportunities that strengthen our business with complementary technologies and greater market access, specifically in relation to the operating room segment of our global business. It is rare to find a business that fits our criteria as well as RESORBA does. We have known RESORBA for a number of years as a result of our LiquiBand® relationship, and I am confident that the enlarged AMS Group will benefit from a wide range of commercial opportunities that will enable us to continue the strong progress made in recent years."

Placing of 47,236,112 new Ordinary Shares in AMS at a price of 72 pence per share to raise approximately £34.0 million in connection with the proposed acquisition of RESORBA Wundversorgung GmbH & co. KG The Board of AMS (AIM: AMS), the global medical technology company, is pleased to announce today the proposed acquisition of RESORBA, a long established wound care and wound closure business headquartered in Germany for a total cash consideration of €63.8 million (approximately £55 million) on a debt-free, cash-free basis to be paid, in full, on completion. To fund the acquisition, the Board of AMS also announces today a non pre-emptive institutional placing (the "Placing") of 47,236,112 new Ordinary Shares in AMS (the "Placing Shares") at a price of 72 pence per Placing Share (the "Placing Price"), to raise approximately £34.0 million (£30.5 million net of acquisition and placing expenses), together with a €25.0 million term loan facility. • The acquisition of RESORBA fulfils all of AMS's strategic acquisition criteria and provides a number of commercial synergy opportunities as it: • Broadens the Group's technology portfolio in both wound care and wound closure; • Provides direct sales capability into the operating room in Germany, Czech Republic and Russia; • Provides significant cross-selling opportunities and product development potential; • Provides access to a new market - oral surgery; • Leverages AMS's global distribution network and regulatory expertise to bring existing RESORBA products to new markets; and • Provides development opportunities in the short, medium and long term • RESORBA is well known to AMS as it currently distributes its LiquiBand® wound closure product and has done for more than eight years • Acquisition is expected to be earnings per share enhancing in the twelve months ending 31 December 20121 • Senior management of RESORBA will be joining the Enlarged Group and investing a material proportion of their net proceeds from the Acquisition in AMS shares • Significant shareholder support for the Placing

http://investegate.co.uk/Article.aspx?id=201112020700162417T

http://b2icontent.irpass.cc/1988%2F130796.pdf?AWSAccessKeyId=1Y51NDPSZK99KT3F8VG2&Expires=1322817518&Signature=FBkdnDJpMWDd%2FLfh%2BvXObZhDfQQ%3D

lionsleeps - good morning. Expert in ZAM! - Most definitely not - I have kept an eye on them and done a bit of reading . It seems an interesting business and I am quite keen on such projects as we all need fed and that number is increasing by the second. My only concern is the corruption in many avenues of African business, politics etc and the very slow way Governments go about making decisions. I havnt invested yet as tied up elsewhere - it continues to be on my watch list. The BoD seem an experienced bunch and the Zambian economy seems to have some positive upward movement in as much as I can tell - with that it may do quite nicely down the line.

Annual Report & Accounts & Annual General Meeting Zambeef (AIM: ZAM), the fully integrated agri-business with operations in Zambia, Nigeria and Ghana, is pleased to announce that the Annual Report & Accounts (the "Annual Report") for the year ended September 30, 2011 is now available on the Company's website at www.zambeefplc.com and will be sent to all shareholders in due course. The Annual Report includes information pertaining to the resolutions to be voted upon, and notice of, the Group's Annual General Meeting (the "AGM") which will be held at the Taj Pamodzi Hotel, Addis Ababa Drive, Lusaka, Zambia on Thursday, December 22, 2011 at 10.00 hours CAT. The record date is December 26, 2011 and dividends will be paid on or before February 29, 2012.

http://www.investegate.co.uk/Article.aspx?id=201112020700162420T

Shares in Carpathian (CPT) slid rose 0.01p to 0.1p as the commercial property investment company announced the sale of the Babilonas Shopping Centre in Lithuania, for 24.1 million euros (21,5 million pounds), 900,000 euros less than the valuation given to the property a year earlier. Despite this, the company will still realise net equity of 5 million euros after sales costs and senior debt is repaid. The company added it continues to review its working capital requirements, with a view of making further distributions to its shareholders.

HSBC upgrades International Personal Finance from neutral to overweight, target price cut from 365p to 250p.

Brewin Dolphin upgrades Consort Medical from hold to buy, target price raised from 530p to 600p.

Could be one to watch. Coverage For the year ended 31st August, XCAP Securities (XCAP) reported a 57% reduction in pre-tax losses to 1.4 million pounds on the back of a 10-fold jump in revenue to 8.8 million pounds. The corporate finance team successfully completed over 20 transactions raising 52 million pounds for its 28 clients, while the market making team also performed strongly, increasing its stock coverage from 215 in 2010 to over 300. Since the period end, XCAP successfully raised 1.4 million pounds, the proceeds of which will be used to enhance the company's relationships with its Middle Eastern network. XCAP shares rose 0.25p to 1.875p.

Mark Holleran, Executive Chairman, commented: "Despite extremely challenging conditions the Company has continued to grow and expand its business divisions over the last 12 months. The dedication of employees and executive management during the course of the year has been outstanding, and our business model puts us in a strong position to capitalise on opportunities that arise moving forward."

Final results for year ended 31 August 2011 XCAP (AIM: XCAP) is a financial services group offering full service stockbroking, fund management, corporate advisory and market making services presents its results for the year ended 31 August 2011. Highlights and Summary Information · Revenue for the period increased to £8.8 million (2010: £0.8 million); · Loss after tax decreased to £1.0 million (2010: £2.8 million) which includes one off non-recurring costs of £1.3 million incurred in the period; · Mark to market adjustment on balance sheet holdings and the effect of share based payments have increased the loss for the period by £0.3 million and £0.2 million respectively; · Net assets increased to £5.0 million (2010: £1.2 million) with no long term liabilities; · A strong performance from the market making team with stock coverage increasing to over 300 stocks (December 2010: 215 stocks); · Corporate finance team successfully completed over 20 transactions raising over £52 million during the year and increased its retained client base to 28 clients; · Stockbroking revenue for the period increased to £4.3 million (2010: £0.5 million); and · The Company successfully raised approximately £1.4 million post year end principally to strengthen the balance sheet and further enhance the Company's relationships with its Middle Eastern network. Please note that the comparatives the comparatives in these financial statements cover a 15 month period from 1 June 2009 to 31 August 2010. The Company commenced trading on 17 May 2010.

http://www.investegate.co.uk/Article.aspx?id=201112010700191229T

MT - Howdy - yes its been a good chart since the lows of 148 ish

In order to focus on its specialty polymer business, Yule Catto (YULC) has sold its pharmaceutical chemicals division Uquifa for 35 million pounds. The decision follows the acquisition of German rubber glove manufacturer PolymerLatex earlier this year for 443 million euros (380.3 million pounds). The consideration consists of an initial payment of 28.6 million pounds in cash, with the remainder paid in three years time. The shares climbed 4.9p to 175p.

Nicholas Hobson, CEO of Fenner said "This is a significant development for the Fenner Dunlop Engineered Conveyor Solutions offering in the Americas. We have again expanded our capabilities and have broadened our offer to manage the life cycle of our customers' conveyors. This acquisition further consolidates Fenner Dunlop's position as the leading supplier of conveyor products and services to the North American markets."

Acquisition of Allison Custom Fabrication, Inc. ("Allison") Fenner is pleased to announce that today its wholly owned subsidiary Fenner Dunlop Americas, Inc., ("Fenner Dunlop") has acquired substantially all of the operating assets of the business being conducted under the name "Allison Custom Fabrication" from a group of related privately owned entities based in Allison, Pennsylvania. The unaudited value of the gross assets being acquired was $6.471m as at 31 December 2010. Allison specialises in the design, engineering, machining and metal fabrication of customised material handling equipment, primarily for the mining markets of Pennsylvania and West Virginia. It has a strong reputation amongst its customers in the underground coal industry for responsive and technically advanced engineering solutions for conveying systems and structure. This latest acquisition will strengthen the Fenner Dunlop strategy of being the supplier of choice for Engineered Conveyor Solutions in the Americas. Combining Fenner Dunlop and Allison will enable mining customers to enjoy integrated solutions for improving the safety and total cost of ownership of materials handling, in both underground and above ground applications.

http://www.investegate.co.uk/Article.aspx?id=201112010700111244T